NEW YORK, August 12, 2013 /PRNewswire/ --
Today, Analysts' Corner announced new research reports highlighting BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX), Exelixis, Inc. (NASDAQ: EXEL), Idenix Pharmaceuticals, Inc. (NASDAQ: IDIX), Puma Biotechnology, Inc. (NYSE: PBYI), and Halozyme Therapeutics, Inc. (NASDAQ: HALO). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.
BioCryst Pharmaceuticals, Inc. Research Report
On August 5, 2013, BioCryst Pharmaceuticals, Inc. (BioCryst) announced that underwriters of the Company's recent public offering of its common stock have fully exercised their option to purchase additional 600,000 shares. The Company expects $20.2 million of total gross proceeds from the offering to BioCryst, which includes proceeds from the exercise of the over-allotment option. BioCryst stated that the offering, including the sale of additional shares will close on August 6, 2013 subject to customary closing conditions and it intends to use net proceeds of the same towards second generation hereditary angioedema compounds and pre commercialization activities related to intravenous peramivir. The Full Research Report on BioCryst Pharmaceuticals, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.analystscorner.com/r/full_research_report/f9b1_BCRX]
Exelixis, Inc. Research Report
On August 6, 2013, Exelixis, I
|SOURCE Analysts' Corner|
Copyright©2012 PR Newswire.
All rights reserved